DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aralast ( Alpha 1-Antitrypsin) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Aralast™ was evaluated for up to 96 weeks in 27 subjects with a congenital deficiency of (alpha)1-PI and clinically evident emphysema. The number of subjects with an adverse event, regardless of causality, was 22 of 27 (81.5%). The number of subjects with an adverse event deemed possibly, probably, or definitely related to study drug was 7 of 27 (25.9%).

The frequency of infusions associated with an adverse event, regardless of causality, was 108 of 1127 (9.6%) infusions administered per protocol. The most common symptoms were pharyngitis (1.6%), headache (0.7%), and increased cough (0.6%). Symptoms of bronchitis, sinusitis, pain, rash, back pain, viral infection, peripheral edema, bloating, dizziness, somnolence, asthma, and rhinitis were each associated with >/= 0.2% of infusions. All symptoms were mild to moderate in severity.

The overall frequency of adverse events deemed to be possibly, probably, or definitely related to study drug was 15 of 1127 (1.3%) infusions. The most common symptoms included headache (0.3%) and somnolence (0.3%). Symptoms of chills and fever, vasodilation, dizziness, pruritus, rash, abnormal vision, chest pain, increased cough, and dyspnea were each associated with one (0.1%) infusion. Five (5) of 27 (18.5%) subjects experienced eight (8) serious adverse reactions during the study. None of these were considered to be causally related to the administration of Aralast™.

Twenty-six (26) of 27 (96.3%) subjects experienced a total of 94 upper and lower respiratory-tract infections during the 96-week study (median: 3.0; range: 1 - 8; mean ± SD: 3.6 ± 2.3 infections). Twenty-eight (29.8%) of the respiratory infections occurred in 19 (70.4%) subjects during the first 24 weeks of the 96-week study suggesting that the risk of infection did not change with time on Aralast™. In a post-hoc analysis, subjects experienced a range of 0 to 8 exacerbations of COPD over the 96-week study with a median of less than one exacerbation per year (median: 0.61; mean ± SD: 0.83 ± 0.87 exacerbations per year).

Treatment-emergent elevations (> two times the upper limit of normal) in aminotransferases (ALT or AST), up to 3.7 times the upper limit of normal, were noted in 3 of 27 (11.1%) subjects. Elevations were transient lasting three months or less. No subject developed any evidence of viral hepatitis or hepatitis serocon-version while being treated with Aralast™, including 13 evaluable subjects who were not vaccinated against hepatitis B.

No clinically relevant alterations in blood pressure, heart rate, respiratory rate, or body temperature occurred during infusion of Aralast™. Mean hematology and laboratory parameters were little changed over the duration of the study, with individual variations not clinically meaningful.

During the initial 10 weeks of the study, subjects were randomized to receive either Aralast™ or a commercially available preparation of (alpha)1-PI (Prolastin®). Both products were well tolerated with the frequency, severity, and symptomatology of adverse reactions similar in both groups. There were no serious adverse events in the group receiving Aralast™. There were two serious adverse events in the control group, one of which was considered to be possibly related to the control drug and included chest pain, dyspnea, and bilateral pulmonary infiltrates. In addition, one subject in the control group became seropositive to Parvovirus B-19. No seroconversions were observed during the entire 96 week study that were attributable to Aralast™. No subject developed an antibody to (alpha)1-PI.



REPORTS OF SUSPECTED ARALAST SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Aralast. The information is not vetted and should not be considered as verified clinical evidence.

Possible Aralast side effects / adverse reactions in 74 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-06

Patient: 74 year old male

Reactions: Death

Adverse event resulted in: death

Suspect drug(s):
Aralast



Possible Aralast side effects / adverse reactions in 74 year old male

Reported by a consumer/non-health professional from United States on 2011-10-12

Patient: 74 year old male weighing 94.0 kg (206.8 pounds)

Reactions: Myocardial Infarction, Cardiac Disorder, Arrhythmia

Adverse event resulted in: death, hospitalization

Suspect drug(s):
Aralast

Other drugs received by patient: Digoxin; Tikosyn; Bisoprolol; Dabigatran



Possible Aralast side effects / adverse reactions in 83 year old female

Reported by a consumer/non-health professional from United States on 2012-02-22

Patient: 83 year old female

Reactions: Death

Adverse event resulted in: death

Suspect drug(s):
Aralast



See index of all Aralast side effect reports >>

Drug label data at the top of this Page last updated: 2006-03-23

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014